The role of bone in CKD-mediated mineral and vascular disease
- 29 August 2014
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 30 (9) , 1379-1388
Abstract
Cardiovascular disease is the leading cause of death in pediatric patients with chronic kidney disease (CKD), and vascular calcifications start early in the course of CKD. Based on the growing body of evidence that alterations of bone and mineral metabolism and the therapies designed to treat the skeletal consequences of CKD are linked to cardiovascular calcifications, the Kidney Disease, Improving Global Outcomes (KDIGO) working group redefined renal osteodystrophy as a systemic disorder of mineral and bone metabolism due to CKD, and this newly defined disorder is now known as “chronic kidney disease-mineral bone disorder (CKD-MBD)”. Elevated fibroblast growth factor 23 (FGF23), a bone-derived protein, is the first biochemical abnormality to be associated with CKD-MBD, and high FGF23 levels correlate with increased cardiovascular morbidity and mortality, suggesting that bone is central to both initiating and perpetuating the abnormal mineral metabolism and vascular disease in CKD. The current standard therapies for CKD-MBD affect FGF23 levels differently; non-calcium-based binders with or without concurrent use of dietary phosphate restriction reduce FGF23 levels, while calcium-based binders seem to either increase or have no effect on FGF23 levels. Active vitamin D sterols increase FGF23 levels, whereas therapy with calcimimetics decreases FGF23 levels. Thus, the appropriate therapy that will minimize the rise in FGF23 and prevent cardiovascular morbidity remains to be defined.Keywords
This publication has 99 references indexed in Scilit:
- Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyBMC Nephrology, 2013
- Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the communityKidney International, 2013
- Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living IndividualsJACC, 2012
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney diseaseBone, 2009
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA proteinNature, 1997